Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune response monitoring after COVID-19 vaccination in children with cancer
NL-OMON52106Phase 4Completed
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- Jul 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of tozinameran and elasomeran in coronavirus disease 2019 (COVID-19) (5 cohorts), sponsored by Princess Máxima Center for Pediatric Oncology. Primary endpoint: Antibody-based immune response at 28 days after second vaccination. Started Jul 2021; status: completed.
02
Drugs
tozinameranelasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON52106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52106.